Open Label Study

An open label study is a clinical trial design in which both the investigators and the participants know which treatment each participant is receiving. Participants and the clinicians who give the treatment are not blinded or masked. Outcome assessment can still be blinded, as in the PROBE design described below, and in a randomized open label trial the upcoming assignment should still be concealed until each participant is enrolled.

Open label designs are common in clinical research, particularly when blinding is impractical, unethical, or unnecessary. Many interventions, such as surgical procedures, physical therapy programs, dietary changes, or devices, cannot be convincingly masked. Some early phase drug trials also use open label designs to focus on safety and dosing without the added complexity and cost of blinding. However, the absence of blinding introduces the potential for bias at multiple levels, from participant expectations and behavior changes to investigator assessments and outcome reporting. Understanding these biases is essential for correctly interpreting the results of open label trials, which constitute a substantial fraction of the clinical evidence base.

In an open label trial, participants are assigned to treatment groups (either randomly or through other allocation methods), but no effort is made to conceal which treatment each participant receives. Open label does not remove the need for allocation concealment: in a randomized open label trial, the upcoming assignment should still be hidden until the participant is irrevocably enrolled, to prevent selection bias. Some open label studies have a single arm and no comparator at all. Participants know their treatment, clinicians know what they are administering, and outcome assessors typically know the group assignment as well.

This transparency affects several aspects of the trial. Participants who know they are receiving an active treatment may report greater improvement due to placebo effects or expectation bias, while those who know they are receiving the control treatment may report worse outcomes or drop out at higher rates. Investigators who are aware of group assignments may unintentionally provide different levels of attention, encouragement, or supplementary care to participants in different groups. Outcome assessors who know the treatment assignment may interpret ambiguous findings more favorably for the group they expect to perform better, a phenomenon known as detection bias or ascertainment bias.

To mitigate these concerns, some open label trials use blinded outcome assessment, in which the individuals who evaluate outcomes are kept unaware of treatment assignment even though participants and treating clinicians are not. This approach is sometimes called PROBE (Prospective Randomized Open Blinded Endpoint) design and can substantially reduce detection bias for endpoints judged by an assessor, such as adjudicated clinical events or graded images, while maintaining the practical advantages of an open label format. It does not blind participants or clinicians, so it does not address performance bias, and it cannot protect outcomes that unblinded participants report themselves, such as pain or quality of life.

Open label extension studies are a related design in which participants who have completed a blinded trial are offered the opportunity to continue receiving the experimental treatment in an unblinded fashion. These extensions provide long term safety data and may support continued access to effective treatments, though they lack a concurrent comparator group and are subject to all the biases of open label designs.

Use an open label design when blinding is technically infeasible (for example, comparing surgery to physical therapy), when the study focuses on safety or pharmacokinetic parameters rather than efficacy outcomes influenced by participant expectations, or in early phase trials where establishing proof of concept and dosing is the primary objective. When an open label design is necessary, incorporate blinded outcome assessment for endpoints that an assessor judges, and prefer objective endpoints where they answer the question, because a blinded assessor cannot protect outcomes that participants report themselves.

A common mistake is treating results from open label trials as equivalent to those from double blind trials when assessing treatment efficacy, particularly for subjective outcomes such as pain, quality of life, or functional improvement. Open label designs are prone to overestimating treatment effects for these outcomes: meta epidemiological studies have found larger average effects in trials without blinding, especially for subjective outcomes, although the size of this bias varies between studies. Another error is failing to implement blinded outcome assessment when it would be feasible, missing an opportunity to strengthen the study's internal validity. Researchers sometimes also neglect to discuss the limitations of the open label design in their publications, leaving readers without the context needed to properly weigh the findings. In open label extension studies, a common mistake is drawing efficacy conclusions without acknowledging the lack of a concurrent control group.

A pharmaceutical company conducts a Phase III trial comparing a new injectable biologic therapy to a standard oral medication for rheumatoid arthritis. Because the routes of administration differ (injection versus oral tablet), double blinding would require a double dummy design with both an active injection plus placebo tablet in one arm and a placebo injection plus active tablet in the other. The company determines that this complexity would increase costs and burden on participants, so they opt for an open label design with blinded assessment of radiographic joint damage (the primary endpoint). Clinical response rates (secondary endpoints) are assessed by the treating physician, who is not blinded. The results show less radiographic joint damage with the biologic, a finding protected from detection bias by the blinded assessment, but the physician assessed clinical response rates must be interpreted cautiously because the physicians knew the treatment.